



Cosmetic Ingredients-Copper Tripeptide-1 《化妆品用原料 三肽-1铜》

National Medical Products Administration

Release Date: Apr 7, 2026
Implementation Date: May 1, 2027

Translated by ChemLinked

Disclaimer


ChemLinked provides translation services to assist clients in understanding the content of regulatory documents. We strive for the accuracy and reliability of our translations, but we do not warrant the accuracy, completeness, or suitability of the translated content.

Clients are responsible for the risks inherent in utilizing our translation services and should consult with professional legal advisors as required. ChemLinked disclaims any liability for any losses or damages arising from the use of our translation services.

Nondisclosure:

You may not disclose this document to anyone else without the written permission of ChemLinked.

For further clarification and questions, you can read our [Privacy Policies](#) or contact us at contact@chemlinked.com



You can now catch up with the latest updates of China CSAR on ChemLinked:



Stay tuned for more translations:

We will provide English translations of CSAR and supporting rules.



Watch our webinars:

Interpretation of China's Cosmetic Supervision and Administration Regulation



Check out the breaking news:

China Finalises the Long-Awaited Cosmetic Supervision and Administration Regulation



Visit the featured page for more information:

Featured — China Cosmetic Regulatory Reform Tracking

ICS 71.100.70

CCS Y 42

YY

Pharmaceutical Industry Standard of the People's Republic of China

YY/T 10005-2026

Cosmetic Ingredients—Copper Tripeptide-1

Issued on 2026-04-03

Implemented on 2027-05-01

Issued by National Medical Products Administration

Contents

Foreword	II
Introduction	III
1 Scope	1
2 Normative References	1
3 Terms and Definitions	1
4 Basic Information	2
5 Requirements	2
6 Test Methods	3
7 Marking, Packaging, Transportation, Storage and Shelf Life	5
Annex A (Normative) Determination of Copper, Tripeptide-1, and Copper Tripeptide-1	
Contents	6
References	14

Foreword

This document was drafted in accordance with the provisions of GB/T 1.1-2020 *Directives for Standardization - Part 1: Rules for the Structure and Drafting of Standardizing Documents*.

Attention is drawn to the possibility that some of the contents of this document may be the subject of patent rights. The issuing body of this document shall not be held responsible for identifying any or all such patent rights.

This document was proposed by the National Medical Products Administration (NMPA).

This document is under the jurisdiction of the Sub-Technical Committee on Ingredients and Packaging Materials of the Technical Committee on Cosmetic Standardization under the NMPA.

The drafting units of this document are as follows: Shandong Institute for Food and Drug Control, Shandong Jitai Biotech Co., Ltd., Shandong Freda Biotechnology Co., Ltd., Zhejiang Institute for Food and Drug Control, Shanghai Institute for Drug Control, and Tianjin Taipu Pharmaceutical Co., Ltd.

The main drafters of this document are as follows: Li Qiyan, Yu Haiying, Jiang Yaqi, Zhang Liangyu, Lin Yujia, Wang Weijian, Dong Xueju, Jin Ming, Cheng Qiaoyuan, Zheng Rong, and Chen Wei.

Make Sure Your Products Entering Global Market with Compliance

What we can do for you?



- + Responsible person (RP) service in China
- + Cosmetic formula and label compliance review
- + Product registration and notification
- + New cosmetic ingredient (NCI) registration and notification
- + Ingredient safety information submission
- + Cosmetic efficacy evaluation



- + Cosmetic formula and label compliance review
- + EDI Notification
- + Cosmetic QC test service
- + Functional cosmetic registration
- + Ingredients registration by ICID



- + Marketing license application
- + Cosmetics notification
- + Ingredients analysis and full ingredient list translation
- + Cosmetic test service
- + Label & advertisement review



- + Responsible Person (RP) service in the EU & UK
- + Cosmetic Product Notification Portal (CPNP)
- + Cosmetic Product Safety Report (CPSR)
- + Preparation of Product Information File (PIF)



- + Cosmetic formula and label compliance review
- + FDA Voluntary Cosmetic Registration Program (VCRP)
- + California Safe Cosmetics Program (CSCP)
- + Toxicological Risk Assessment (TRA)
- + INCI application

What makes us unique?

- ✔ Connect with officials and associations
- ✔ Flexible consulting service packages
- ✔ Team of qualified toxicology and regulatory experts





ICS 71.100.70

CCS Y 42

中 华 人 民 共 和 国 医 药 行 业 标 准

YY/T 10005-2026

化妆品用原料 三肽-1 铜

Cosmetic Ingredients—Copper Tripeptide-1

2026-04-03 发布

2027-05-01 实施

国家药品监督管理局 发布

目 次

前 言.....	II
引 言.....	III
1 范围.....	4
2 规范性引用文件.....	4
3 术语和定义.....	4
4 基本信息.....	4
5 要求.....	5
6 试验方法.....	3
7 标志、包装、运输、贮存、保质期.....	8
附 录 A（规范性）铜、三肽-1和三肽-1铜含量测定方法.....	6
参 考 文 献.....	15

前 言

本文件按照GB/T 1.1—2020《标准化工作导则 第1部分：标准化文件的结构和起草规则》的规定起草。

请注意本文件的某些内容可能涉及专利。本文件的发布机构不承担识别专利的责任。

本文件由国家药品监督管理局提出。

本文件由国家药品监督管理局化妆品标准化技术委员会原料和包装材料分技术委员会归口。

本文件起草单位：山东省食品药品检验研究院、山东济肽生物科技有限公司、山东福瑞达生物科技有限公司、浙江省食品药品检验研究院、上海市药品检验研究院、天津泰普制药有限公司。

本文件主要起草人：李启艳、于海英、蒋亚奇、张良雨、林钰镓、王维剑、董雪菊、靳明、程巧鹭、郑荣、陈蔚。



Free



Free trial



Standard



Corporate



Special

SUBSCRIBE TO CHEMLINKED NOW

REMOVE COSMETIC REGULATORY BARRIERS EXPEDITE GLOBAL MARKET ACCESS

- In-time regulatory information and market access requirements
- Supported by local and experienced technically adept technical team
- Strategic partnerships with competent authorities and industrial associations worldwide
- Customized consulting service for complete compliance solutions.

OUR SERVICES



Information & Knowledge

News, Reports, Expert Analysis
Pedia-articles



Databases

Regulatory Database, English Translations
Inventories/Lists



Solutions

Regulatory Compliance Service, On-demand
Translation, Advertisement Service, Tailor-made
Service, E-commerce Solution



Training

Webinars, Online Course
Offline Events